Development of quantitative evaluating methods for chemotherapy-induced peripheral neuropathy with analyses of onco-neuro-immunological pathophysiology

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07378
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Showa University
• Principal Investigator: Ariizumi Hirotsugu 昭和大学, 医学部, 講師 (50621190)
• Co-Investigator(Kenkyū-buntansha): 角田 卓也 昭和大学, 医学部, 教授 (30275359) ; 吉村 清 昭和大学, 大学共同利用機関等の部局等, 教授 (30346564)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 化学療法誘発性末梢神経障害 / 神経損傷バイオマーカー

Outline of Final Research Achievements

Purpose of this study is developing of diagnostic method for chemotherapy-induced peripheral neuropathy with blood biomarker. Among patients with solid tumor who received chemotherapy including oxaliplatin, we analyzed state of condition of numbness with questionnaires, and stocked patients’ serum before and after chemotherapy. Serum levels of molecule X and Y were significantly lower in patients with numbness compared with patients without numbness. However, only measuring molecule X and Y could not identified patient with chemotherapy-induced peripheral neuropathy, because range of these molecules were overlapped between patients with and without chemotherapy-induced peripheral neuropathy. Serum level of molecule X before chemotherapy was significantly lower in patients who onset chemotherapy-induced peripheral neuropathy after chemotherapy. molecule X might be predictor for chemotherapy-induced peripheral neuropathy.

Free Research Field

腫瘍学

Academic Significance and Societal Importance of the Research Achievements

血液中の神経損傷バイオマーカーの測定が、化学療法誘発性末梢神経障害の診断補助法や発症予測手段となりうる可能性が示唆された。